The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against ...

HIV effort. More people than ever are receiving antiretroviral treatment and have viral suppression. Deaths from AIDS are at their lowest level for two decades. Yet despite this encouraging progress, ...

Global HIV rates drop 20 but challenges persist in ending AIDS by 2030 Explore breakthroughs like lenacapavir prevention ...

Corkscrew is coming home to Lake Norman. The longtime wine bar has inked a deal for an 1,800-square-foot space in ...

Expect scattered rain showers. The low will be 66°. Moderate air quality (51-100) Primary pollutant O₃ 86 μg/m³ Amount of moisture present in the air relative to the maximum amount of moisture the air ...

Kirtland coach Tiger LaVerde knows how dangerous an undefeated team in an upswing program that is playing its first state ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...